Boston Scientific's Public Offering: Prelude to Deals?
Executive Summary
After Boston Scientific's successful public offering, Boston's stock price was up $46.50 on July 16, 1999, suggesting investors are growing confident that Boston Scientific can rejoin the ranks as one of the leading big-cap device companies in terms of earnings and growth. For non-investors, the public offering raises another question: will Boston Scientific also return to form as one of the device industry's most aggressive acquirers of other companies?You may also be interested in...
December ANDA Rush Is Largest In Two Years
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Korean Pharma Highlights R&D Progress, 2020 Strategy At JPM
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
Buckle Up, Industry: EWG Finds ‘4 Million Asbestos Fiber Structures’ In Makeup For Young Girls
US House Energy and Commerce Chair Frank Pallone took note on 16 January of the Environmental Working Group’s finding of asbestos contamination in a “Princess” makeup set intended for young girls. Rep. Debbie Dingell, D-MI, will speak to the test results first, pushing her own legislation that would require asbestos testing of talc-containing children’s cosmetics in accordance with preferred methods.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports